FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CD9-ADAMTS12

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CD9-ADAMTS12
FusionPDB ID: 14742
FusionGDB2.0 ID: 14742
HgeneTgene
Gene symbol

CD9

ADAMTS12

Gene ID

928

81792

Gene nameCD9 moleculeADAM metallopeptidase with thrombospondin type 1 motif 12
SynonymsBTCC-1|DRAP-27|MIC3|MRP-1|TSPAN-29|TSPAN29PRO4389
Cytomap

12p13.31

5p13.3-p13.2

Type of geneprotein-codingprotein-coding
DescriptionCD9 antigen5H9 antigenBA-2/p24 antigenCD9 antigen (p24)antigen CD9cell growth-inhibiting gene 2 proteinleukocyte antigen MIC3motility related protein-1tetraspanin-29A disintegrin and metalloproteinase with thrombospondin motifs 12ADAM-TS 12ADAM-TS12ADAMTS-12a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12
Modification date2020032720200313
UniProtAcc

Q8TCZ2

Main function of 5'-partner protein: FUNCTION: Plays a role in a late step of leukocyte extravasation helping cells to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1 (By similarity). Homophilic adhesion molecule, but these interactions may not be required for cell aggregation (By similarity). {ECO:0000250}.

P58397

Main function of 5'-partner protein: FUNCTION: Metalloprotease that may play a role in the degradation of COMP. Cleaves also alpha-2 macroglobulin and aggregan. Has anti-tumorigenic properties. {ECO:0000269|PubMed:16611630, ECO:0000269|PubMed:17895370, ECO:0000269|PubMed:18485748}.
Ensembl transtripts involved in fusion geneENST idsENST00000481267, ENST00000009180, 
ENST00000382518, ENST00000382515, 
ENST00000352040, ENST00000504830, 
ENST00000504582, ENST00000515401, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score13 X 11 X 7=10019 X 7 X 7=441
# samples 149
** MAII scorelog2(14/1001*10)=-2.83794324189103
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/441*10)=-2.29278174922785
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CD9 [Title/Abstract] AND ADAMTS12 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CD9 [Title/Abstract] AND ADAMTS12 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CD9(6334700)-ADAMTS12(33684160), # samples:2
Anticipated loss of major functional domain due to fusion event.CD9-ADAMTS12 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CD9-ADAMTS12 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CD9-ADAMTS12 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CD9-ADAMTS12 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCD9

GO:0007155

cell adhesion

7511626

HgeneCD9

GO:0007342

fusion of sperm to egg plasma membrane involved in single fertilization

14575715

HgeneCD9

GO:0051271

negative regulation of cellular component movement

8478605

HgeneCD9

GO:0090331

negative regulation of platelet aggregation

18541721

TgeneADAMTS12

GO:0030167

proteoglycan catabolic process

17895370

TgeneADAMTS12

GO:0032331

negative regulation of chondrocyte differentiation

22247065

TgeneADAMTS12

GO:0050727

regulation of inflammatory response

23019333

TgeneADAMTS12

GO:0051603

proteolysis involved in cellular protein catabolic process

16611630

TgeneADAMTS12

GO:0071773

cellular response to BMP stimulus

22247065

TgeneADAMTS12

GO:1901509

regulation of endothelial tube morphogenesis

17895370

TgeneADAMTS12

GO:1902203

negative regulation of hepatocyte growth factor receptor signaling pathway

17895370

TgeneADAMTS12

GO:1902548

negative regulation of cellular response to vascular endothelial growth factor stimulus

17895370

TgeneADAMTS12

GO:2001113

negative regulation of cellular response to hepatocyte growth factor stimulus

17895370



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:6334700/chr5:33684160)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CD9 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ADAMTS12 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000382518CD9chr126334700+ENST00000504830ADAMTS12chr533684160-841561124747611504
ENST00000382518CD9chr126334700+ENST00000352040ADAMTS12chr533684160-451461124745061419
ENST00000009180CD9chr126334700+ENST00000504830ADAMTS12chr533684160-80302265143761441
ENST00000009180CD9chr126334700+ENST00000352040ADAMTS12chr533684160-41292265141211356

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000382518ENST00000504830CD9chr126334700+ADAMTS12chr533684160-0.0004108290.99958915
ENST00000382518ENST00000352040CD9chr126334700+ADAMTS12chr533684160-0.0014378470.99856216
ENST00000009180ENST00000504830CD9chr126334700+ADAMTS12chr533684160-0.0002614110.99973863
ENST00000009180ENST00000352040CD9chr126334700+ADAMTS12chr533684160-0.0009991320.99900085

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CD9-ADAMTS12

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CD9chr126334700ADAMTS12chr53368416022658EQETNNNNSSFYTDSVNISQKQELWR
CD9chr126334700ADAMTS12chr533684160611121EQETNNNNSSFYTDSVNISQKQELWR

Top

Potential FusionNeoAntigen Information of CD9-ADAMTS12 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CD9-ADAMTS12_6334700_33684160.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CD9-ADAMTS12chr126334700chr533684160226HLA-C04:04SFYTDSVNI0.44460.7657918
CD9-ADAMTS12chr126334700chr533684160226HLA-C14:02SFYTDSVNI0.15070.9341918
CD9-ADAMTS12chr126334700chr533684160226HLA-C14:03SFYTDSVNI0.15070.9341918

Top

Potential FusionNeoAntigen Information of CD9-ADAMTS12 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CD9-ADAMTS12_6334700_33684160.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CD9-ADAMTS12chr126334700chr533684160226DRB1-0305NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0305NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0338NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0340NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0340NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0401NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0401NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0401SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0401NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0407NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0407SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0407NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0409NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0409NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0419NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0419NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0419SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0422NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0422NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0431NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0431NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0431SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0433NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0433NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0433SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0433NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0434NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0434NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0434SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0434NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0435NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0435NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0435SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0435NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0438NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0438NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0438SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0438NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0443NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0443NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0461NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0461NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0461SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0462NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0462NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0462NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0462SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0463NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0463NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0463SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0463NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0464NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0464NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0464SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0464NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0466NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0466NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0466SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0466NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0472NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0472NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0472SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0472NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0474NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0474NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0474SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0474NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0475NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0475NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0475SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0476NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-0476NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-0476SSFYTDSVNISQKQE823
CD9-ADAMTS12chr126334700chr533684160226DRB1-0476NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB1-0487NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1117YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1152YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1179NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1179NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB1-1333NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1337NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1401YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1401FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1404YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1404FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1405YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1407YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1407FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1408YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1409NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1411YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1418YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1419NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1423YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1426YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1426FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1428YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1428FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1431YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1432YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1432FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1435YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1435FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1438YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1438FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1439YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1439FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1443YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1445YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1446NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB1-1450YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1450FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1454YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1454FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1455YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1456YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1458YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1458FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1459YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1460YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1460FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1461YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1461FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1462YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1462FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1464YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1465YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1468YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1470YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1470FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1471YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1471FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1472YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1475YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1475FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1482YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1482FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1482SFYTDSVNISQKQEL924
CD9-ADAMTS12chr126334700chr533684160226DRB1-1486YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1486FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1487YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1487FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1488YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1488FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1490YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1490FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1491YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1493YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1495YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1495FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1496YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1497YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1497FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB1-1499YTDSVNISQKQELWR1126
CD9-ADAMTS12chr126334700chr533684160226DRB1-1499FYTDSVNISQKQELW1025
CD9-ADAMTS12chr126334700chr533684160226DRB3-0101NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0101NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0101NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0104NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0104NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0104NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0105NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0105NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0105NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0108NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0108NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0108NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0109NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0109NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0111NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0111NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0111NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0112NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0112NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0112NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0113NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0113NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0113NNNSSFYTDSVNISQ520
CD9-ADAMTS12chr126334700chr533684160226DRB3-0114NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0114NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0202NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0205NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0205NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0210NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0211NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0212NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0213NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0213NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0215NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0215NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0216NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0217NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0217NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0218NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0219NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0219NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0220NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0222NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0222NNSSFYTDSVNISQK621
CD9-ADAMTS12chr126334700chr533684160226DRB3-0223NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0225NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0303NSSFYTDSVNISQKQ722
CD9-ADAMTS12chr126334700chr533684160226DRB3-0303NNSSFYTDSVNISQK621

Top

Fusion breakpoint peptide structures of CD9-ADAMTS12

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6297NNSSFYTDSVNISQCD9ADAMTS12chr126334700chr533684160226

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CD9-ADAMTS12

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6297NNSSFYTDSVNISQ-7.9962-8.1096
HLA-B14:023BVN6297NNSSFYTDSVNISQ-5.70842-6.74372
HLA-B52:013W396297NNSSFYTDSVNISQ-6.83737-6.95077
HLA-B52:013W396297NNSSFYTDSVNISQ-4.4836-5.5189
HLA-A11:014UQ26297NNSSFYTDSVNISQ-10.0067-10.1201
HLA-A11:014UQ26297NNSSFYTDSVNISQ-9.03915-10.0745
HLA-A24:025HGA6297NNSSFYTDSVNISQ-6.56204-6.67544
HLA-A24:025HGA6297NNSSFYTDSVNISQ-5.42271-6.45801
HLA-B44:053DX86297NNSSFYTDSVNISQ-7.85648-8.89178
HLA-B44:053DX86297NNSSFYTDSVNISQ-5.3978-5.5112
HLA-A02:016TDR6297NNSSFYTDSVNISQ-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CD9-ADAMTS12

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CD9-ADAMTS12chr126334700chr533684160918SFYTDSVNIGCTTCTACACAGACAGTGTTAACATCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CD9-ADAMTS12chr126334700chr5336841601025FYTDSVNISQKQELWTCTACACAGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGC
CD9-ADAMTS12chr126334700chr5336841601126YTDSVNISQKQELWRACACAGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGG
CD9-ADAMTS12chr126334700chr533684160520NNNSSFYTDSVNISQATAATAATTCCAGCTTCTACACAGACAGTGTTAACATCTCCCAGA
CD9-ADAMTS12chr126334700chr533684160621NNSSFYTDSVNISQKATAATTCCAGCTTCTACACAGACAGTGTTAACATCTCCCAGAAGC
CD9-ADAMTS12chr126334700chr533684160722NSSFYTDSVNISQKQATTCCAGCTTCTACACAGACAGTGTTAACATCTCCCAGAAGCAAG
CD9-ADAMTS12chr126334700chr533684160823SSFYTDSVNISQKQECCAGCTTCTACACAGACAGTGTTAACATCTCCCAGAAGCAAGAGC
CD9-ADAMTS12chr126334700chr533684160924SFYTDSVNISQKQELGCTTCTACACAGACAGTGTTAACATCTCCCAGAAGCAAGAGCTAT

Top

Information of the samples that have these potential fusion neoantigens of CD9-ADAMTS12

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCACD9-ADAMTS12chr126334700ENST00000009180chr533684160ENST00000352040TCGA-A7-A4SD-01A

Top

Potential target of CAR-T therapy development for CD9-ADAMTS12

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneCD9chr12:6334700chr5:33684160ENST00000009180+2813_3358229.0TransmembraneHelical
HgeneCD9chr12:6334700chr5:33684160ENST00000382518+3913_3358229.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CD9-ADAMTS12

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CD9-ADAMTS12

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource